Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective dropped by investment analysts at Piper Sandler from $20.00 to $7.00 in a report released on Friday, The Fly reports. Piper Sandler’s price objective points to a potential upside of 442.64% from the stock’s previous close. A number of other brokerages have also recently issued […]
Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports. According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product pipeline consists of a […]
Equities analysts expect that Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) will post earnings per share of ($0.25) for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Cardiff Oncology’s earnings, with estimates ranging from ($0.28) to ($0.22). Cardiff Oncology reported earnings of ($0.17) per share during the same quarter last […]
Wall Street brokerages expect Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Rating) to report earnings of ($0.23) per share for the current quarter, Zacks reports. Two analysts have issued estimates for Cardiff Oncology’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.24). Cardiff Oncology reported earnings of […]